Join the 'Non-Small Cell Lung Cancer' group to help and get support from people like you.

Non-Small Cell Lung Cancer Blog

Related terms: Cancer, Lung, Non-Small Cell, Lung Cancer, Non-Small Cell, NSCLC

Can Statins Help Lower Lung Cancer Death Risk?

Posted 1 May 2015 by Drugs.com

FRIDAY, May 1, 2015 – Taking the cholesterol-lowering medications known as statins for a year before getting a diagnosis of lung cancer was associated with a 12 percent lower risk of dying from that cancer, new research suggests. The researchers from Northern Ireland also found indications that those who had a minimum of 12 statin prescriptions filled after being diagnosed with lung cancer saw their lung cancer death risk drop by as much as 19 percent. But, study lead author Chris Cardwell stressed that the degree of the association seen between statin use and a lower risk for lung cancer death was "relatively small." And while the study found an association between statin use and a lower risk of lung cancer death, it wasn't designed to prove a cause-and-effect relationship. Cardwell said there are any number of other differences between patients who take statins and patients who don't ... Read more

Related support groups: Lipitor, Simvastatin, Crestor, Pravastatin, Atorvastatin, Zocor, Lovastatin, Lung Cancer, Non-Small Cell Lung Cancer, Vytorin, Rosuvastatin, Red Yeast Rice, Livalo, Pravachol, Caduet, Simcor, Lescol, Lescol XL, Mevacor, Pitavastatin

Drugs Show Promise for Some Advanced Lung Cancers

Posted 29 Apr 2015 by Drugs.com

WEDNESDAY, April 29, 2015 – Two experimental drugs may help patients whose lung cancer has become resistant to the latest available treatments, separate studies say. Both drugs showed benefits for patients with advanced lung cancer who develop a particular mutation that makes their tumors resistant to recently approved drugs called EGFR inhibitors. Currently, little can be done for those patients aside from chemotherapy. "And those chemotherapy agents don't do a great job," said Dr. Ramaswamy Govindan, an oncologist at Washington University School of Medicine in St. Louis. The two drugs are not "magic bullets," said Govindan, who wrote an editorial published with the studies in the April 30 issue of the New England Journal of Medicine. "But in the long struggle against lung cancer, this is a significant step," Govindan said. Among all people who develop non-small-cell lung cancer – by ... Read more

Related support groups: Lung Cancer, Tarceva, Non-Small Cell Lung Cancer, Erbitux, Iressa, Cetuximab, Gefitinib, Gilotrif, Erlotinib, Vectibix, Tykerb, Vandetanib, Afatinib, Panitumumab, Lapatinib, Caprelsa

Opdivo Approval Expanded to Include Lung Cancer

Posted 4 Mar 2015 by Drugs.com

WEDNESDAY, March 4, 2015 – U.S. Food and Drug Administration approval of Opdivo (nivolumab) has been expanded to include advanced non-small cell lung cancer (NSCLC), the agency said Wednesday in a news release. Lung cancer is the leading cause of cancer death in the United States, having been diagnosed more than 224,000 times and causing more than 159,000 deaths in 2014, the FDA said. NSCLC is the most common type, affecting seven of eight people with lung cancer. Opdivo inhibits a protein that prevents the immune system from attacking cancer cells, the agency said. The drug is sanctioned for people who have been treated with platinum-based chemotherapy. Opdivo was clinically compared to another anti-cancer drug, docetaxel, in a study involving more than 270 people with NSCLC. People who received Opdivo lived an average of 3.2 months longer than people given docetaxel, the FDA said. ... Read more

Related support groups: Non-Small Cell Lung Cancer, Opdivo, Nivolumab

FDA Expands Approved use of Opdivo (nivolumab) to Treat Lung Cancer

Posted 4 Mar 2015 by Drugs.com

March 4, 2015 – The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Lung cancer is the leading cause of cancer death in the United States, with an estimated 224,210 new diagnoses and 159,260 deaths in 2014. The most common type of lung cancer, NSCLC affects seven out of eight lung cancer patients, occurring when cancer forms in the cells of the lung. Opdivo works by inhibiting the cellular pathway known as PD-1 protein on cells that blocks the body’s immune system from attacking cancerous cells. Opdivo is intended for patients who have previously been treated with platinum-based chemotherapy. “The FDA worked proactively with the company to facilitate the early submission and review of this important ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Opdivo, Nivolumab

FDA Expands Approved use of Cyramza to Treat Aggressive Non-Small Cell Lung Cancer

Posted 12 Dec 2014 by Drugs.com

The U.S. Food and Drug Administration today expanded the approved use of Cyramza (ramucirumab) to treat patients with metastatic non-small cell lung cancer (NSCLC). The most common type of lung cancer, NSCLC occurs when cancer cells form in the tissues of the lung. The National Cancer Institute estimates that 224,210 Americans will be diagnosed and 159,260 will die from lung cancer in 2014. Cyramza works by blocking the blood supply that fuels tumor growth. The drug is intended for patients whose tumor has grown (progressed) during or following treatment with platinum-based chemotherapy, and it is to be used in combination with docetaxel, another type of chemotherapy. “Today’s approval is the third indication that Cyramza has received in 2014,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Th ... Read more

Related support groups: Non-Small Cell Lung Cancer, Cyramza, Ramucirumab

Cyramza Approval Expanded to Include Non-Small Lung Cancer

Posted 12 Dec 2014 by Drugs.com

FRIDAY, Dec. 12, 2014 – U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small cell lung cancer (NSCLC), the agency said Friday. NSCLC, the most common form of lung cancer, will be diagnosed in an estimated 224,000 Americans this year, and about 159,000 Americans will die from it, the FDA said, citing U.S. National Cancer Institute projections. Cyramza is designed to block the blood supply that feeds tumors. It's intended for people whose tumors have grown during or after treatment with other drugs. Cyramza was first approved in April to treat advanced cancers of the stomach or gastrointestinal tract, and approval was widened in November to include advanced gastric cancers. Clinical side effects have included a drop in germ-fighting white blood cells, inflammation of the mouth's lining, severe bleeding, ... Read more

Related support groups: Non-Small Cell Lung Cancer, Cyramza, Ramucirumab

FDA Approves Zykadia (ceritinib) for Metastatic Non-Small Cell Lung Cancer

Posted 29 Apr 2014 by Drugs.com

April 29, 2014 – The U.S. Food and Drug Administration today granted accelerated approval to Zykadia (ceritinib) for patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC). Zykadia is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that blocks proteins that promote the development of cancerous cells. It is intended for patients with metastatic ALK-positive NSCLC who were previously treated with crizotinib, the only other approved ALK tyrosine kinase inhibitor. Lung cancer is the leading cause of cancer-related deaths among men and women. According to the National Cancer Institute, an estimated 224,210 Americans will be diagnosed with lung cancer, and 159,260 will die from the disease this year. About 85 percent of lung cancers are NSCLC, making it the most common type of lung cancer. However, only 2-7 percent of patients with NSCLC ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer

Chemo Might Give Certain Lung Cancer Patients an Edge

Posted 8 Apr 2014 by Drugs.com

TUESDAY, April 8, 2014 – Cancer specialists have been unsure about how best to treat certain patients with an advanced form of lung cancer. Now, a new analysis of existing research finds that traditional chemotherapy outperforms newer, targeted treatments in delaying the time until the cancer worsens for these patients. However, chemo doesn't extend their survival, the review found. Patients with non-small cell lung cancer make up 85 percent to 90 percent of lung cancer patients. Some of them have a mutation in a gene that makes their tumors more responsive to medications known as epidermal growth factor receptor tyrosine kinase inhibitors. But most patients with non-small cell lung cancer do not have this mutation, and doctors have been unsure whether this larger group of patients should get chemo or the targeted medication. "In our opinion, conventional chemotherapy is a better ... Read more

Related support groups: Non-Small Cell Lung Cancer

Experimental Drug Shows Promise for Drug-Resistant Lung Cancer

Posted 26 Mar 2014 by Drugs.com

WEDNESDAY, March 26, 2014 – A new drug may help lung cancer patients when they become resistant to the first-line medication crizotinib, researchers find. Although crizotinib (brand name Xalkori) causes regression of a specific type of lung cancer, patients become resistant to it within about a year. But the new drug, ceritinib, seems effective against this type of lung cancer – called advanced ALK-positive non-small cell lung cancer – according to the results of early trials. "Ceritinib is even effective after the first-generation drug crizotinib has stopped working," said lead researcher Dr. Alice Shaw, an associate professor of medicine at Harvard Medical School in Boston. Preliminary results from this study led the U.S. Food and Drug Administration to give ceritinib a "breakthrough therapy" designation and led the drug's manufacturer to recommend accelerated approval, she said. ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Xalkori, Crizotinib

Breath Test May Detect Signs of Lung Cancer: Study

Posted 28 Jan 2014 by Drugs.com

TUESDAY, Jan. 28, 2014 – A simple breath test might reveal if a person has early-stage lung cancer, according to a new study. Researchers tested the exhaled breath of people with suspicious lung lesions that were detected on CT scans. The breath was tested for levels of four cancer-specific substances, called "carbonyls." The breath samples were analyzed using a special device developed at the University of Louisville. Having elevated levels of three of the four carbonyls was predictive of lung cancer in 95 percent of patients, while having normal levels of these substances was predictive of a noncancerous growth in 80 percent of patients, the researchers found. Elevated carbonyl levels returned to normal after lung cancer patients had surgery to remove the cancer, according to the study, which was to be presented Tuesday at the Society of Thoracic Surgeons annual meeting in Orlando, ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Diagnosis and Investigation

Gilotrif Approved for Late-Stage Lung Cancer

Posted 14 Jul 2013 by Drugs.com

FRIDAY, July 12 – The drug Gilotrif (afatinib) has been approved by the U.S. Food and Drug Administration to treat spreading cases of non-small cell lung cancer (NSCLC) caused by certain gene mutations, the agency said Friday. The treatment, given priority FDA review, was sanctioned for tumors that express certain epidermal growth factor receptor (EGFR) mutations, as detected by a newly approved diagnostic, the agency said in a news release. Lung cancer is the number one cause of cancer-related death in both men and women, the FDA said. The disease is likely to be diagnosed in some 228,190 people this year, and is predicted to kill about 159,480, the U.S. National Cancer Institute said. EGFR mutations are found in about 10 percent of NSCLC cases. Gilotrif is designed to block proteins that spur development of cancer cells, the FDA said. The drug was approved along with a companion ... Read more

Related support groups: Non-Small Cell Lung Cancer

New Drug May Help Fight Certain Advanced Lung Cancers

Posted 3 Jun 2013 by Drugs.com

MONDAY, June 3 – For patients struggling with a common and deadly form of lung cancer, adding the drug ganetespib to a standard chemotherapy drug may boost survival, new research suggests. The finding centers on a class of medications known as heat shock protein 90 (Hsp90) inhibitors, and it's the first time in more than 10 years that researchers have uncovered a better way to treat this group of patients. The findings were slated for presentation Monday in Chicago at the annual meeting of the American Society of Clinical Oncology. "This is the first randomized study to demonstrate therapeutic benefit with a heat shock protein inhibitor in patients with cancer," study lead author Dr. Suresh Ramalingam, a professor of medical oncology at the Winship Cancer Institute of Emory University, in Atlanta, said in an ASCO news release. The study focused on patients with a form of non-small cell ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer

New Drug May Help Immune System Fight Cancer

Posted 16 May 2013 by Drugs.com

THURSDAY, May 16 – An experimental drug that taps the power of the body's immune system to fight cancer is shrinking tumors in patients for whom other treatments have failed, an early study shows. The drug binds to a protein called PD-L1 that sits on the surface of cancer cells and makes them invisible to the immune system, almost like a cloaking device. "That [the protein] allows the tumor cell to grow unchecked and cause harm to the patient," said study author Dr. Roy Herbst, chief of medical oncology at Yale University. But with the protein blocked, the immune system can see and destroy cancer cells. Of 140 patients in the pilot safety study, 29 (or 21 percent) initially saw significant tumor shrinkage after at least three months on the medication. Researchers say 26 patients have continued to respond over time, including some who have been on the drug for more than a year. One ... Read more

Related support groups: Cancer, Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Melanoma, Gastric Cancer

Test Approved to Detect Faulty Lung Cancer Gene

Posted 16 May 2013 by Drugs.com

THURSDAY, May 16 – The U.S. Food and Drug Administration has approved a test designed to detect a faulty gene that's present in about 10 percent of cases of non-small cell lung cancer (NSCLC). The cobas EGFR Mutation Test, a companion diagnostic to the approved cancer drug Tarceva (erlotinib), detects a mutation in the epidermal growth factor receptor (EGFR) gene, the FDA said in a news release. Lung cancer is the leading cause of cancer-related death for both men and women, accounting for about 228,000 annual cases in the United States. Some 85 percent of lung cancers are NSCLC, the FDA said. In approving the new diagnostic, the FDA also sanctioned expanded use for Tarceva as a first-line treatment for people with NSCLC that has spread to other parts of the body and who have the mutated gene, the agency said. The new diagnostic is produced by California-based Roche Molecular Systems. ... Read more

Related support groups: Non-Small Cell Lung Cancer, Diagnosis and Investigation

Freezing Treatment May Help Destroy Lung Tumors: Study

Posted 15 Apr 2013 by Drugs.com

SUNDAY, April 14 – A method designed to target, freeze and destroy a tumor's cellular function seems effective in combating lung tumors, a small ongoing study finds. At least in the short-run – meaning three months after the procedure – the intervention known as "cryoablation" appeared to kill all targeted tumors that had spread to the lung from elsewhere, preliminary results suggest. However, some patients developed new tumors in that time period, the researchers noted. The study authors cautioned that while the initial findings are encouraging, the treatment should not be seen as a cure for this type of metastatic (spreading) lung disease. Rather, they said that for certain patients who may not be eligible for more standard surgical approaches, the therapy has potential as an alternative means for offering an improved quality of life for a longer period of time. "'Promising' is the ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer

Page 1 2 3 4 5 6 Next

Ask a Question

Further Information

Related Condition Support Groups

Lung Cancer

Related Drug Support Groups

methotrexate, Tarceva, Avastin, Taxol, Taxotere, cisplatin, Xalkori, Gemzar, cyclophosphamide, view more... gemcitabine, paclitaxel, capecitabine, Iressa, Cyramza, docetaxel, Alimta, Gilotrif, gefitinib, erlotinib, cetuximab, Abraxane, bevacizumab, Platinol, vinorelbine, crizotinib, Navelbine, ramucirumab, amifostine, afatinib, pemetrexed, Trexall, Methotrexate LPF Sodium, Opdivo, Docefrez, Zykadia, Ethyol, ceritinib, porfimer, paclitaxel protein-bound, nivolumab, Onxol, Folex PFS, Photofrin, Platinol-AQ